Pharmacokinetics and Safety of BI 695502 in Healthy Subjects: a Randomized, Single-blind, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study

Trial Profile

Pharmacokinetics and Safety of BI 695502 in Healthy Subjects: a Randomized, Single-blind, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Pharmacokinetics
  • Acronyms INVICTAN-1
  • Most Recent Events

    • 16 Nov 2016 According to Boehringer Ingelheim Pharmaceuticals media release, data from this trial were presented at the American Association of Pharmaceutical Scientists Annual Meeting.
    • 16 Nov 2016 Results published in a Boehringer Ingelheim Pharmaceuticals media release.
    • 08 Feb 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top